UBS AM
HZNP

UBS AM’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

UBS AM’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,111,231
Closed -$129M – 2641
2023
Q3 		$129M Buy
1,111,231
+83,525
+8% +$8.97M 0.06% 348
2023
Q2 		$112M Hold
1,027,706
– – 0.05% 363
2023
Q1 		$112M Buy
1,027,706
+20,476
+2% +$2.26M 0.05% 363
2022
Q4 		$115M Buy
1,007,230
+22,248
+2% +$1.85M 0.06% 352
2022
Q3 		$61M Buy
+984,982
New +$68.8M 0.03% 487
2019
Q2 		– Sell
-131,561
Closed -$3.48M – 2910
2019
Q1 		$3.48M Buy
131,561
+8,386
+7% +$199K ﹤0.01% 1283
2018
Q4 		$2.41M Buy
123,175
+15,227
+14% +$298K ﹤0.01% 1362
2018
Q3 		$2.11M Buy
107,948
+3,182
+3% +$60.5K ﹤0.01% 1482
2018
Q2 		$1.73M Sell
104,766
-9,952
-9% -$152K ﹤0.01% 1570
2018
Q1 		$1.63M Buy
114,718
+10,694
+10% +$158K ﹤0.01% 1561
2017
Q4 		$1.52M Buy
104,024
+10,780
+12% +$151K ﹤0.01% 1554
2017
Q3 		$1.18M Buy
93,244
+5,104
+6% +$64.9K ﹤0.01% 1635
2017
Q2 		$1.05M Sell
88,140
-91,238
-51% -$1.13M ﹤0.01% 1639
2017
Q1 		$2.65M Sell
179,378
-65,155
-27% -$1.06M ﹤0.01% 1233
2016
Q4 		$3.96M Sell
244,533
-461,399
-65% -$8.37M ﹤0.01% 1047
2016
Q3 		$12.8M Sell
705,932
-13,252
-2% -$259K 0.01% 823
2016
Q2 		$11.8M Buy
719,184
+231,170
+47% +$3.74M 0.01% 839
2016
Q1 		$8.09M Buy
488,014
+388,001
+388% +$6.79M 0.01% 895
2015
Q4 		$2.17M Buy
100,013
+17,173
+21% +$334K ﹤0.01% 1407
2015
Q3 		$1.64M Buy
82,840
+7,256
+10% +$229K ﹤0.01% 1515
2015
Q2 		$2.63M Buy
75,584
+27,184
+56% +$830K ﹤0.01% 1280
2015
Q1 		$1.26M Buy
48,400
+13,600
+39% +$249K ﹤0.01% 1546
2014
Q4 		$449K Buy
34,800
+5,200
+18% +$65.1K ﹤0.01% 2002
2014
Q3 		$363K Buy
29,600
+16,100
+119% +$187K ﹤0.01% 2036
2014
Q2 		$214K Buy
+13,500
New +$193K ﹤0.01% 2379

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS AM's HZNP Position: Q4 2023 in Review

UBS AM sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,111,231 shares — an estimated $129M sold.

UBS AM first reported a position in HZNP in Q2 2014 and held it in 25 quarters. The position peaked at $129M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • UBS AM reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • UBS AM sold 1,111,231 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $129M.
  • UBS AM first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 25 quarters.
  • UBS AM's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $129M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on UBS AM's 13F filing for Q4 2023, filed 14 Feb 2024.